Sentences with phrase «ipilimumab resulted»
A recent study showed that T - VEC in combination with ipilimumab resulted in an overall response rate of 50 %, durable response rate of 44 %, and tolerable safety profile in patients with advanced melanoma, said Georgina Long, BSc, PhD, MBBS, of the Melanoma Institute Australia in Sydney.
http://www.cancernetwork.com/ Not exact matches
Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time at the ESMO 2016 Congress in Copenhagen.
The results of the trial, which compared a combination of checkpoint inhibitors ipilimumab and nivolumab against ipilimumab alone in previously untreated patients, were presented today at the 2015 Annual Meeting of the American Association for Cancer Research and have been simultaneously published in the New England Journal of Medicine.
The first such drug, called ipilimumab (Yervoy), developed out of Allison's basic science research, showed much lower response rates against advanced melanoma than those obtained with targeted drugs, but long - term follow - up found that 22 percent of those treated with Yervoy survived at least four years, unprecedented results for the disease.
Dr Butler said: «Our results show that patients benefited from pembrolizumab regardless of whether or not they had been pre-treated with ipilimumab.»
A cohort of patients treated with the immune checkpoint inhibitor ipilimumab (207 patients) showed similar results.
Dr Larkin said: «Results from our large analysis of pre-defined sub-groups of patients with advanced melanoma provide evidence that suggests the combination of the two drugs consistently improves progression - free survival across a range of sub-groups, including patients with poor prognostic factors, when compared with either nivolumab or ipilimumab alone.»
Professor Peter Naredi, the ECCO scientific co-chair of the Congress, who was not involved in the research, commented: «Although the CheckMate 067 study has already reported that a combination of two checkpoint inhibitors, nivolumab and ipilimumab, is superior to either drug alone, the results presented here in Vienna have important clinical implications.
These adverse events resulted in 52 percent of patients on ipilimumab discontinuing treatment before its completion, including 39 percent of patients during the first four doses of ipilimumab.
Perhaps most promising are results from a combination treatment using both ipilimumab and nivolumab, which the FDA approved in 2015 for previously untreated (first - line) unresectable or metastatic melanoma for patients without a BRAF mutation.
This anti-PD-1 antibody works in a complementary fashion to ipilimumab and can be combined with it for more powerful results, as has been recently shown by a clinical trial conducted by CRI Scientific Advisory Council associate director Jedd Wolchok.
The positive results from the two phase III studies of ipilimumab were made possible in part through the evolution of the clinical science, which is based on new models of academic - industry partnership to advance immunotherapy development.
At a very early follow - up, nivolumab treatment resulted in a statistically significant 12 - month relapse - free survival rate compared with ipilimumab.